MaxCyte Inc (MXCT) Business Payback Period

Corporate emblem and logo of MaxCyte Inc (MXCT)

This daily price chart illustrates the price action of MaxCyte, Inc. (MXCT), which currently maintains a P/E ratio of -3.90. The business is protected by stable Western legal frameworks and the humanitarian status of its shipments. Growth is driven by the expansion of its electroporation license pool and milestone payments. MaxCyte, Inc. (MXCT) leads the cell modification sector, securing long-term revenue through royalties from the largest developers of gene therapies.

MXCT: MaxCyte P/E Multiple 07/04/2022 - 11/10/2026

Analytical breakdowns for MaxCyte, Inc (MXCT)

- market price and analyst price targets:
Market Price maxcyte.com|MXCT - Price Target Chart
- market capitalization details:
Market Capitalization MaxCyte, Inc.|MXCT - Real Price to Acquire Entire Company
- book capitalization data:
Book Price of a Share MaxCyte|MXCT - Book Capitalization|Market Capitalization to Book Value maxcyte.com|MXCT - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio MaxCyte, Inc.|MXCT - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital MaxCyte Inc|MXCT - Company Debts|Debt to Book Value MaxCyte, Inc.|MXCT - Company Long-Term Debts|Short-Term Debt MaxCyte|Immediate Liquidity Ratio maxcyte.com
- earnings and valuation multiples information:
MXCT - Net Profit|Company Profit Forecast MaxCyte, Inc.|MXCT - P/E Multiple|Projected Price to Earnings MaxCyte Inc.|MXCT - PEG Multiple|EV/EBITDA Multiple MaxCyte, Inc.|MXCT - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months MaxCyte|MXCT - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months maxcyte.com|MXCT - Earnings growth in current year|Expected net earnings per share growth next year MaxCyte, Inc.
Comprehensive company analysis:MXCT maxcyte.com
Signature product of MaxCyte Inc

The market values MaxCyte, Inc. (MXCT) through the lens of future technological breakthroughs, balancing risk against growth potential. This price-to-earnings ratio compares the company's current market capitalization with net income to determine the cost per unit of profit. High values reflect confidence in the scaling of electroporation royalty streams. However, a lack of new clinical partnerships could lead to an asset revaluation and capital loss.

Key competitors

Market Cap to Earnings abbott.com ABT|Price to Earnings Ratio Thermo Fisher (TMO)|Business Payback Period GE HealthCare Technologies Inc.|Mettler-Toledo International Inc. - Price to Earnings Ratio|Market Price to Net Income Ratio WAT (Waters Technologies)|Bio-Techne Corporation - P/E Multiple|Business Payback Period bruker.com BRKR|AZTA: P/E Multiple|Price to Earnings Ratio Varex Imaging Corp|Price to Earnings Ratio SMLR|BFLY: Company Value to Net Income|Price to Earnings Ratio Mesa Laboratories, Inc. (MLAB)|Price to Earnings Ratio quantum-si.com QSI|P/E Multiple NNOX (Nano-X)|Quanterix Corp. (QTRX) - Market Cap to Earnings|908 Devices Corp - P/E Multiple|CV (CapsoVision Inc) - Price to Earnings Multiple|RPID: P/E Multiple|SEER - Business Payback Period|HYPR (Hyperfine) - P/E Multiple|Price to Earnings Ratio FONAR Corp. (FONR)|P/E Multiple DXR|P/E Multiple spectral-ai.com (MDAI)|Price to Earnings Ratio VivoSim Labs Inc VIVS|aclarion.com - Price to Earnings Ratio|AKYA: Price to Earnings Ratio|Company Value to Net Income THMO (ThermoGenesis Holdings, Inc.)|TLIS: P/E Multiple|Market Cap to Earnings T2 Biosystems Inc (TTOO)